Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 109

Results For "UST"

4813 News Found

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
News | August 06, 2025

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter


Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
News | August 06, 2025

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter


Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
News | August 06, 2025

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine


Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
News | August 06, 2025

Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs

These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs


Revvity launches reagent technology for targeted therapeutics
News | August 06, 2025

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research


Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
News | August 05, 2025

Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr

The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore


Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
News | August 05, 2025

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase


Beta-HPV can directly cause skin cancer in immunocompromised people
News | August 03, 2025

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally


Illumina launches new assay for tumor profiling
News | August 03, 2025

Illumina launches new assay for tumor profiling

he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements